ARWR Receives EU Approval
Arrowhead Pharmaceuticals receives EU marketing authorization for REDEMPLO to reduce triglycerides in adults with Familial Chylomicronemia Syndrome
ARWR Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)